Antibodies
5 February 2014
Seattle Genetics Achieves Sales Milestone Under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda5 February 2014
Elusys Completes Enrollment in Three Phase 3 Safety Studies of Its Anthrax Anti-Toxin, ETI-204, in Adult Volunteers4 February 2014
TRACON Pharmaceuticals Initiates Phase 1b Study of TRC105 in Patients With Advanced Soft Tissue Sarcoma3 February 2014
Omeros Announces Positive Data after Completion of Dosing in Phase 1 Clinical Trial with OMS72130 January 2014
XBiotech and European Medicines Agency (EMA) Agree on Phase III Registration Study for Treatment of Colorectal Cancer25 January 2014
CHMP recommends EU approval of a new formulation of Roche’s MabThera for patients with non-Hodgkin lymphoma23 January 2014
The exponential growth of the field of antibody-drug conjugates provides plenty of business opportunities22 January 2014
Kolltan Pharmaceuticals Initiates Phase 1 Study of KTN3379, A Dual-Mechanism Anti-ErbB3 Monoclonal Antibody20 January 2014
Biocon Introduces CANMAbTM – World’s First Biosimilar Trastuzumab for Treating Breast Cancer in India17 January 2014
Takeda Announces the New Drug Application Approval of ADCETRIS (brentuximab vedotin) in Japan for the Treatment of Malignant Lymphoma14 January 2014
Genmab Announces DuoBody Platform Collaboration With Lilly14 January 2014
Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular DegenerationNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports